
## Amy Peacock

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5126679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health, 2017, 5, e1192-e1207.	2.9	1,020
2	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 2018, 113, 1905-1926.	1.7	685
3	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. The Lancet Global Health, 2017, 5, e1208-e1220.	2.9	334
4	New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet, The, 2019, 394, 1668-1684.	6.3	195
5	Global, regional, and countryâ€level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	1.7	178
6	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health, The, 2018, 3, e341-e350.	4.7	172
7	A systematic review of injecting-related injury and disease among people who inject drugs. Drug and Alcohol Dependence, 2017, 171, 39-49.	1.6	163
8	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. The Lancet Gastroenterology and Hepatology, 2019, 4, 435-444.	3.7	145
9	The Subjective Physiological, Psychological, and Behavioral Riskâ€Taking Consequences of Alcohol and Energy Drink Coâ€Ingestion. Alcoholism: Clinical and Experimental Research, 2012, 36, 2008-2015.	1.4	87
10	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. JAMA Psychiatry, 2020, 77, 493.	6.0	83
11	Illicit drug use and harms in Australia in the context of <scp>COVID</scp> â€19 and associated restrictions: Anticipated consequences and initial responses. Drug and Alcohol Review, 2020, 39, 297-300.	1.1	83
12	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. International Journal of Drug Policy, 2019, 73, 172-184.	1.6	67
13	The Impact of Alcohol and Energy Drink Consumption on Intoxication and Risk-Taking Behavior. Alcoholism: Clinical and Experimental Research, 2013, 37, 1234-1242.	1.4	63
14	â€~High' risk? A systematic review of the acute outcomes of mixing alcohol with energy drinks. Addiction, 2014, 109, 1612-1633.	1.7	60
15	Patterns of use and motivations for consuming alcohol mixed with energy drinks Psychology of Addictive Behaviors, 2013, 27, 202-206.	1.4	58
16	Energy drink ingredients. Contribution of caffeine and taurine to performance outcomes. Appetite, 2013, 64, 1-4.	1.8	51
17	Characteristics and circumstances of synthetic cannabinoid-related death. Clinical Toxicology, 2020, 58, 368-374.	0.8	50
18	New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015. Drug and Alcohol Dependence, 2016, 161, 110-118.	1.6	46

#	Article	IF	CITATIONS
19	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. Drug and Alcohol Dependence, 2020, 207, 107793.	1.6	44
20	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. Drug and Alcohol Dependence, 2016, 162, 79-87.	1.6	40
21	Motivations for new psychoactive substance use among regular psychostimulant users in Australia. International Journal of Drug Policy, 2017, 43, 23-32.	1.6	36
22	Alcohol use among young Australian adults in May–June 2020 during the COVIDâ€19 pandemic: a prospective cohort study. Addiction, 2021, 116, 3398-3407.	1.7	34
23	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. Pain Medicine, 2018, 19, 533-540.	0.9	32
24	Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. Drug and Alcohol Review, 2018, 37, S203-S205.	1.1	32
25	Mortality among people with regular or problematic use of amphetamines: a systematic review and metaâ€analysis. Addiction, 2019, 114, 1738-1750.	1.7	32
26	Changes in illicit drug use and markets with the COVIDâ€19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016–20. Addiction, 2022, 117, 182-194.	1.7	31
27	Motivations, substance use and other correlates amongst property and violent offenders who regularly inject drugs. Addictive Behaviors, 2015, 45, 207-213.	1.7	30
28	Dayâ€byâ€day variation in affect, arousal and alcohol consumption in young adults. Drug and Alcohol Review, 2015, 34, 588-594.	1.1	29
29	A Clobal Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. Journal of Infectious Diseases, 2019, 220, 78-90.	1.9	29
30	Changes in mental health and help-seeking among young Australian adults during the COVID-19 pandemic: a prospective cohort study. Psychological Medicine, 2023, 53, 687-695.	2.7	29
31	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry,the, 2018, 5, 155-166.	3.7	28
32	I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances. International Journal of Drug Policy, 2017, 40, 44-49.	1.6	22
33	<scp>COVID</scp> â€19 vaccination among people who inject drugs: Leaving no one behind. Drug and Alcohol Review, 2021, 40, 517-520.	1.1	22
34	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. International Journal of Drug Policy, 2020, 76, 102619.	1.6	21
35	Allâ€cause and causeâ€specific mortality among people with regular or problematic cocaine use: a systematic review and metaâ€analysis. Addiction, 2021, 116, 725-742.	1.7	21
36	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse Treatment, 2015, 58, 51-61.	1.5	20

#	Article	IF	CITATIONS
37	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. International Journal of Drug Policy, 2020, 77, 102656.	1.6	20
38	Selfâ€Reported Riskâ€Taking Behavior During Matchedâ€Frequency Sessions of Alcohol Versus Combined Alcohol and Energy Drinks Consumption: Does Coâ€Ingestion Increase Riskâ€Taking?. Alcoholism: Clinical and Experimental Research, 2015, 39, 911-918.	1.4	19
39	Behavioral measures of state impulsivity and their psychometric properties: A systematic review. Personality and Individual Differences, 2018, 135, 67-79.	1.6	19
40	Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia. Drug and Alcohol Dependence, 2019, 204, 107556.	1.6	19
41	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. The Lancet Global Health, 2020, 8, e76-e91.	2.9	19
42	Cognitive Impairment Following Consumption of Alcohol With and Without Energy Drinks. Alcoholism: Clinical and Experimental Research, 2015, 39, 733-742.	1.4	18
43	Tobacco and e-cigarette use amongst illicit drug users in Australia. Drug and Alcohol Dependence, 2016, 159, 35-41.	1.6	18
44	Alcohol Use Disorders in the Draft ICD-11, and How They Compare with DSM-5. Current Addiction Reports, 2018, 5, 257-264.	1.6	17
45	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. International Journal of Drug Policy, 2020, 84, 102866.	1.6	17
46	Characteristics and circumstances of death related to gamma hydroxybutyrate (GHB). Clinical Toxicology, 2020, 58, 1028-1033.	0.8	17
47	Trends in methamphetamine use, markets and harms in Australia, 2003–2019. Drug and Alcohol Review, 2022, 41, 1041-1052.	1.1	17
48	Guilt-proneness is associated with the use of protective behavioral strategies during episodes of alcohol use. Addictive Behaviors, 2018, 79, 120-123.	1.7	16
49	Adherence to the Caffeine Intake Guideline during Pregnancy and Birth Outcomes: A Prospective Cohort Study. Nutrients, 2018, 10, 319.	1.7	16
50	Alcohol consumption and consequences in adolescents in 68 low and middle-income countries – a multi-country comparison of risks by sex. Drug and Alcohol Dependence, 2019, 205, 107520.	1.6	16
51	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. International Journal of Drug Policy, 2019, 70, 87-93.	1.6	16
52	Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study. Drug and Alcohol Dependence, 2020, 215, 108204.	1.6	16
53	Typology of Alcohol Mixed with Energy Drink Consumers: Motivations for Use. Alcoholism: Clinical and Experimental Research, 2015, 39, 1083-1092.	1.4	15
54	Energy drink use frequency among an international sample of people who use drugs: Associations with other substance use and well-being. Drug and Alcohol Dependence, 2017, 174, 70-79.	1.6	15

#	Article	IF	CITATIONS
55	Trends in cocaine use, markets and harms in Australia, 2003–2019. Drug and Alcohol Review, 2021, 40, 946-956.	1.1	15
56	<scp>COVID</scp> â€19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout. Drug and Alcohol Review, 2022, 41, 484-487.	1.1	15
57	Awareness of energy drink intake guidelines and associated consumption practices: a cross-sectional study. BMC Public Health, 2015, 16, 6.	1.2	14
58	Young adults who mix alcohol with energy drinks: Typology of risk-taking behaviour. Addictive Behaviors, 2015, 45, 252-258.	1.7	14
59	Typology of alcohol consumers in five Australian nighttime entertainment districts. Drug and Alcohol Review, 2016, 35, 539-548.	1.1	14
60	Perception of intoxication in a field study of the night-time economy: Blood alcohol concentration, patron characteristics, and event-level predictors. Addictive Behaviors, 2018, 76, 195-200.	1.7	14
61	Parental supply of alcohol as a predictor of adolescent alcohol consumption patterns: A prospective cohort. Drug and Alcohol Dependence, 2019, 204, 107529.	1.6	14
62	Self-reported physiological and psychological side-effects of an acute alcohol and energy drink dose. Appetite, 2014, 76, 60-65.	1.8	13
63	Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. International Journal of Drug Policy, 2015, 26, 1265-1272.	1.6	13
64	Investigating Differences Between Drugs Used in the Australian Night-Time Economy: Demographics, Substance Use, and Harm. Substance Use and Misuse, 2017, 52, 71-81.	0.7	13
65	The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing. Drug and Alcohol Review, 2018, 37, 546-556.	1.1	13
66	Profile and correlates of injecting-related injuries and diseases among people who inject drugs in Australia. Drug and Alcohol Dependence, 2020, 216, 108267.	1.6	13
67	Uptake, barriers and correlates of influenza vaccination among people who inject drugs in Australia. Drug and Alcohol Dependence, 2021, 226, 108882.	1.6	13
68	Detecting impairment: Sensitive cognitive measures of dose-related acute alcohol intoxication. Journal of Psychopharmacology, 2015, 29, 436-446.	2.0	12
69	Effectiveness of inpatient withdrawal and residential rehabilitation interventions for alcohol use disorder: A national observational, cohort study in England. Journal of Substance Abuse Treatment, 2018, 88, 1-8.	1.5	12
70	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. Current Addiction Reports, 2018, 5, 464-472.	1.6	12
71	Combining transdermal and breath alcohol assessments, realâ€ŧime drink logs and retrospective selfâ€reports to measure alcohol consumption and intoxication across a multiâ€day music festival. Drug and Alcohol Review, 2021, 40, 1112-1121.	1.1	12
72	Trends in treatment episodes for methamphetamine smoking and injecting in Australia, 2003–2019. Drug and Alcohol Review, 2021, 40, 1281-1286.	1.1	12

Аму Реасоск

#	Article	IF	CITATIONS
73	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. Drug and Alcohol Dependence, 2022, 236, 109494.	1.6	12
74	"High―Motivation for Alcohol: What are the Practical Effects of Energy Drinks on Alcohol Priming?. Alcoholism: Clinical and Experimental Research, 2013, 37, 185-187.	1.4	11
75	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. Drug and Alcohol Dependence, 2016, 166, 125-133.	1.6	11
76	Typology of new psychoactive substance use among the general Australian population. Drug and Alcohol Dependence, 2018, 188, 126-134.	1.6	11
77	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. Addiction, 2018, 113, 1768-1774.	1.7	11
78	Postâ€marketing studies of pharmaceutical opioid abuseâ€deterrent formulations: a framework for research design and reporting. Addiction, 2019, 114, 389-399.	1.7	11
79	Modelling the potential prevention benefits of a treatâ€all hepatitis C treatment strategy at global, regional and country levels: A modelling study. Journal of Viral Hepatitis, 2019, 26, 1388-1403.	1.0	11
80	Protocol for the Data-Linkage Alcohol Cohort Study (DACS): investigating mortality, morbidity and offending among people with an alcohol-related problem using linked administrative data. BMJ Open, 2019, 9, e030605.	0.8	11
81	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug and Alcohol Review, 2015, 34, 611-622.	1.1	10
82	Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. Pain Medicine, 2016, 17, 2003-2016.	0.9	10
83	Nature versus intensity of intoxication: Co-ingestion of alcohol and energy drinks and the effect on objective and subjective intoxication. Drug and Alcohol Dependence, 2017, 180, 292-303.	1.6	10
84	Effectiveness of community psychosocial and pharmacological treatments for alcohol use disorder: A national observational cohort study in England. Drug and Alcohol Dependence, 2018, 186, 60-67.	1.6	10
85	Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. Drug and Alcohol Dependence, 2020, 206, 107697.	1.6	10
86	All-Cause and Overdose Mortality Risk Among People Prescribed Opioids: A Systematic Review and Meta-analysis. Pain Medicine, 2020, 21, 3700-3711.	0.9	10
87	The overall effect of parental supply of alcohol across adolescence on alcoholâ€related harms in early adulthood—a prospective cohort study. Addiction, 2020, 115, 1833-1843.	1.7	10
88	Patterns of smoking and injecting methamphetamine and their association with health and social outcomes. Drug and Alcohol Review, 2021, 40, 1256-1265.	1.1	10
89	Characteristics and circumstances of death related to the selfâ€administration of ketamine. Addiction, 2021, 116, 339-345.	1.7	9
90	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. Drug and Alcohol Dependence, 2021, 228, 109050.	1.6	9

Аму Реасоск

#	Article	IF	CITATIONS
91	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Australian Health Review, 2016, 40, 490.	0.5	8
92	Coâ€ingestion of energy drinks with alcohol and other substances among a sample of people who regularly use ecstasy. Drug and Alcohol Review, 2016, 35, 352-358.	1.1	8
93	Combined use of alcohol and energy drinks: Dose relationship with self-reported physiological stimulation and sedation side effects. Addictive Behaviors, 2017, 71, 68-74.	1.7	8
94	New psychoactive substances: Purchasing and supply patterns in Australia. Human Psychopharmacology, 2017, 32, e2577.	0.7	8
95	Targeting at-risk samples through brief face-to-face interviews in night-time entertainment precincts. Journal of Substance Use, 2018, 23, 353-357.	0.3	8
96	Trajectories of alcoholâ€induced blackouts in adolescence: early risk factors and alcohol use disorder outcomes in early adulthood. Addiction, 2021, 116, 2039-2048.	1.7	8
97	Characteristics of fatal â€~novel' synthetic opioid toxicity in Australia. Drug and Alcohol Dependence, 2022, 232, 109292.	1.6	8
98	New psychoactive substances in Australia: patterns and characteristics of use, adverse effects, and interventions to reduce harm. Current Opinion in Psychiatry, 2020, 33, 343-351.	3.1	7
99	A review of caffeine use as a risk or protective factor for women's health and pregnancy. Current Opinion in Psychiatry, 2017, 30, 253-259.	3.1	7
100	Correlates of higherâ€risk drugâ€related behaviours at music festivals in New South Wales, Australia. Drug and Alcohol Review, 2022, 41, 320-329.	1.1	7
101	A systematic review of event-level measures of risk-taking behaviors and harms during alcohol intoxication. Addictive Behaviors, 2019, 99, 106101.	1.7	6
102	Unintentional and intentional drug poisoning deaths, Australia, 2012–2016: Drug pattern profile and demographic characteristics. Drug and Alcohol Dependence, 2021, 229, 109112.	1.6	6
103	<scp>COVID</scp> â€19 vaccine acceptability among people in Australia who inject drugs: Update from the 2021 Illicit Drug Reporting System interviews. Drug and Alcohol Review, 2022, , .	1.1	6
104	Barriers to helpâ€seeking among music festival attendees in New South Wales, Australia. Drug and Alcohol Review, 2022, 41, 1322-1330.	1.1	6
105	The right place at the right time: The social contexts of combined alcohol and energy drink use. Drugs: Education, Prevention and Policy, 2016, 23, 445-456.	0.8	5
106	Alprazolam use among a sample of Australians who inject drugs: Trends up to six years post regulatory changes. International Journal of Drug Policy, 2020, 79, 102721.	1.6	5
107	Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000–2020. Clinical Toxicology, 2022, 60, 304-310.	0.8	5
108	Profile and correlates of colorimetric reagent kit use among people who use ecstasy/MDMA and other illegal stimulants in Australia. International Journal of Drug Policy, 2021, 97, 103334.	1.6	5

Αму Реасоск

#	Article	IF	CITATIONS
109	Valid Points, But the Trends Remain: A Response to Rossheim, Suzuki, and Thombs (In Press). Alcoholism: Clinical and Experimental Research, 2013, 37, 2171-2174.	1.4	4
110	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamperâ€resistant formulation of controlledâ€release oxycodone. Pharmacoepidemiology and Drug Safety, 2015, 24, 1321-1333.	0.9	4
111	Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. Drug and Alcohol Dependence, 2018, 188, 304-310.	1.6	4
112	Aggression in the Australian night time economy: A comparison of alcohol only versus alcohol and illicit drug consumption. Drug and Alcohol Review, 2019, 38, 744-749.	1.1	4
113	Extraâ€medical use of antipsychotics: what can be learnt from experiences with other prescription medicines?. Addiction, 2020, 115, 1203-1205.	1.7	4
114	The association between parental supply of alcohol and supply from other sources to young people: a prospective cohort. Addiction, 2020, 115, 2140-2147.	1.7	4
115	Concordance between selfâ€reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. Drug and Alcohol Review, 2021, 40, 1349-1353.	1.1	4
116	Epidemiology of Substance Use Internationally. Advances in Prevention Science, 2019, , 19-36.	0.3	4
117	University Students' Views on the Nature of Science and Psychology. Psychology Learning and Teaching, 2011, 10, 128-145.	1.3	3
118	Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. Lancet Psychiatry,the, 2015, 2, 957-959.	3.7	3
119	Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol. BMJ Open, 2018, 8, e020006.	0.8	3
120	Mixing alcohol and energy drinks: associations with risk-taking, alcohol consumption and motivations in a New Zealand sample. Journal of Substance Use, 2020, 25, 157-162.	0.3	3
121	Use of alcohol swabs to clean injecting sites among people who regularly inject drugs in Australia. Drug and Alcohol Review, 2020, 39, 83-92.	1.1	3
122	Patterns and correlates of prescribed and nonâ€prescribed pregabalin use among a sample of people who inject drugs in Australia. Drug and Alcohol Review, 2020, 39, 568-574.	1.1	3
123	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. Drug and Alcohol Dependence, 2020, 209, 107899.	1.6	3
124	Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011–2018. Drug and Alcohol Dependence, 2021, 221, 108636.	1.6	3
125	Effectiveness and framing of pharmaceutical opioid abuseâ€deterrent formulations. Addiction, 2019, 114, 404-405.	1.7	2
126	A Typology of Predictive Risk Factors for NonAdherent Medication-Related Behaviors among Chronic Non-Cancer Pain Patients Prescribed Opioids: A Cohort Study. Pain Physician, 2016, 3;19, E421-E434.	0.3	2

#	Article	IF	CITATIONS
127	Characteristics of fatal tapentadolâ€related toxicity in Australia. Drug and Alcohol Review, 2022, , .	1.1	2
128	Energy drinks, alcohol and cardiovascular functioning. Drug and Alcohol Dependence, 2018, 185, 423-424.	1.6	1
129	What do we know about alcohol mixed with energy drink (AmED) use in Australia? Expanding local evidence. Public Health Research and Practice, 2018, 28, .	0.7	1
130	A Typology of Predictive Risk Factors for Non-Adherent Medication-Related Behaviors among Chronic Non-Cancer Pain Patients Prescribed Opioids: A Cohort Study. Pain Physician, 2016, 19, E421-34.	0.3	1
131	Assessing drivingâ€relevant attentional impairment after a multiday drinking session: A twoâ€phase pilot study. Alcoholism: Clinical and Experimental Research, 2022, 46, 628-640.	1.4	1
132	Prime Time for In Situ Measurement: What Are the Drivers and Implications of Energy Drink Coâ€Ingestion on Alcohol Priming?. Alcoholism: Clinical and Experimental Research, 2016, 40, 2073-2075.	1.4	0
133	Trends in methamphetamine and opioid use among clients of needleâ€syringe programs in Queensland, Australia: 2007–2015. Drug and Alcohol Review, 2019, 38, 159-168.	1.1	0
134	Alcohol Mixed with Energy Drinks and Intoxication. , 2020, , 111-135.		0
135	The experience of physiological and psychosocial alcoholâ€related harms across adolescence and its association with alcohol use disorder in early adulthood: A prospective cohort study. Alcoholism: Clinical and Experimental Research, 2021, 45, 2518-2527.	1.4	0